About T Cell Engagers

T cell engagers are designed to redirect immune effector cells against cancer cells by simultaneously binding to a specific tumor-associated antigen expressed on the cancer cells and the T cell receptor complex on T cells. To date, T cell engagers have demonstrated significant promise for cancer immunotherapy in a variety of advanced solid tumors, but the potential has been limited by toxicity.

Xilio’s Masked T Cell Engagers

Xilio is leveraging its proprietary, clinically validated tumor-activation platform to advance a pipeline of wholly-owned novel masked T cell engager molecules with conditional half-life modulation designed to enable potent, localized T cell activation and tumor cell destruction together with an improved therapeutic index. These programs include bispecific molecules designed using Xilio’s advanced tumor-activated cell engager (ATACR) format, which consists of a T cell engager with a masked CD3 targeting domain, and tri-specific molecules designed using Xilio’s selective effector-enhanced cell engager (SEECR) format, which builds upon the ATACR format by adding co-stimulatory signaling designed to further enhance potency and T cell activation.

Xilio is currently advancing three wholly-owned programs for masked T cell engager molecules targeting the following tumor-associated antigens: PSMA, CLDN18.2 and STEAP1.